Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7491719 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
Nov, 2023
(5 months ago) | |
US7056916 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Dec, 2023
(4 months ago) | |
US7220742 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(1 year, 14 days from now) | |
US7727984 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Jan, 2027
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7246615 | BOEHRINGER INGELHEIM | Atomising nozzle and filter and spray generating device |
May, 2016
(7 years ago) | |
US7104470 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(7 years ago) | |
US5964416 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(7 years ago) | |
US6726124 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(7 years ago) | |
US6176442 | BOEHRINGER INGELHEIM | Device for mounting a component exposed to a pressurized fluid |
Oct, 2016
(7 years ago) | |
US6453795 | BOEHRINGER INGELHEIM | Locking mechanism for a spring-actuated device |
Dec, 2016
(7 years ago) | |
US6149054 | BOEHRINGER INGELHEIM | Mechanical counter for a metering apparatus |
Dec, 2016
(7 years ago) | |
US6846413 | BOEHRINGER INGELHEIM | Microstructured filter |
Aug, 2018
(5 years ago) | |
US6977042 | BOEHRINGER INGELHEIM | Microstructured filter |
Aug, 2018
(5 years ago) | |
US7802568 | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Feb, 2019
(5 years ago) | |
US6988496 | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Feb, 2020
(4 years ago) | |
US7988001 | BOEHRINGER INGELHEIM | Container provided with a pressure equalization opening |
Aug, 2021
(2 years ago) | |
US7786111 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(5 months ago) | |
US8044046 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(5 months ago) | |
US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(3 months from now) | |
US8034809 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(1 year, 14 days from now) | |
US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(1 year, 28 days from now) | |
US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(2 years from now) | |
US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(2 years from now) | |
US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(3 years from now) | |
US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(6 years from now) |
Striverdi Respimat is owned by Boehringer Ingelheim.
Striverdi Respimat contains Olodaterol Hydrochloride.
Striverdi Respimat has a total of 25 drug patents out of which 16 drug patents have expired.
Expired drug patents of Striverdi Respimat are:
Striverdi Respimat was authorised for market use on 31 July, 2014.
Striverdi Respimat is available in spray, metered;inhalation dosage forms.
Striverdi Respimat can be used as treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema.
Drug patent challenges can be filed against Striverdi Respimat from 31 July, 2018.
The generics of Striverdi Respimat are possible to be released after 16 October, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 31 July, 2014
Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema
Dosage: SPRAY, METERED;INHALATION